CYTOF (Altamira Therapeutics) Change In Receivables: $-0.08 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Altamira Therapeutics Change In Receivables?

Altamira Therapeutics CYTOF -0.01% Change In Receivables is $-0.08 Mil as of Jun. 2025. The stock has 4 warning signs investors should review.

Altamira Therapeutics's change in receivables for the quarter that ended in Jun. 2025 was $0.16 Mil. It means Altamira Therapeutics's Accounts Receivable declined by $0.16 Mil from Dec. 2024 to Jun. 2025 .

Altamira Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $-0.28 Mil. It means Altamira Therapeutics's Accounts Receivable increased by $0.28 Mil from Dec. 2023 to Dec. 2024 .

Altamira Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2025 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Altamira Therapeutics's liquidation value for the six months ended in Jun. 2025 was $-3.05 Mil.

Altamira Therapeutics  (OTCPK:CYTOF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Altamira Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Altamira Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Altamira Therapeutics's liquidation value for the quarter that ended in Jun. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.004-3.056+0.75 * 0+0.5 * 0
=-3.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Change In Receivables Related Terms

Altamira Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Change In Receivables Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 -0.37 -0.11 0.02 -0.28

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 0.09 -0.04 -0.24 0.16

Altamira Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.08 Mil mean?
Altamira Therapeutics (CYTOF) has a Change In Receivables of $-0.08 Mil as of Jun. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' Change In Receivables too high?
Altamira Therapeutics' current Change In Receivables is $-0.08 Mil.
How does Altamira Therapeutics' Change In Receivables compare to CARM and PTIX?
Altamira Therapeutics' Change In Receivables of $-0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Altamira Therapeutics and its competitors. Altamira Therapeutics's current Change In Receivables is $-0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current Change In Receivables of $-0.08 Mil. The current Change In Receivables is $-0.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current Change In Receivables is $-0.08 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.